{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T17:16:25Z","timestamp":1787937385318,"version":"build-2784847793"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Regulatory interest in real-world evidence (RWE) to supplement single-arm trials (SATs) in oncology has increased, yet how the Food and Drug Administration (FDA) and European Medicines Agency (EMA) evaluate such evidence remains incompletely understood.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To comprehensively evaluate recent oncology approvals in which SATs were supported by RWE, characterizing regulatory feedback, methodological approaches, role of RWE in decision-making.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We reviewed FDA New Drug Applications and Biologics License Applications (NDAs\/BLAs), and EMA Marketing Authorizations (MAAs) (January 2022-August 2025). Approvals were identified through publicly available FDA and EMA databases. Regulatory documents were screened using predefined RWE- and SAT-related keywords, with full-text review for data extraction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 883 original approvals (553 FDA, 330 EMA), 200 were oncology products (134 FDA, 66 EMA). Eighteen applications (7 FDA, 11 EMA) incorporated SATs supplemented by RWE, representing 15 unique products, predominantly for hematologic malignancies (53.3%). All 15 products included at least 1 RWE approach, and 8 used multiple approaches including historical clinical trial data and literature. Among 25 distinct RWE or observational approaches, 16 (64.0%) were retrospective cohort designs drawing on patient-level data from electronic health records (24.0%), disease (20.0%) or product registries (4.0%), or chart abstractions (28.0%). RWE primarily served as contextual\/supportive evidence (only 2 use cases viewed as providing \u201csubstantial evidence\u201d). Methodological limitations commonly included small sample sizes, population heterogeneity, missing or unmeasured covariates, non-aligned outcome assessments, post-hoc design, and non-contemporaneous treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>RWE is increasingly used to support oncology SATs and holds promise as supportive or contextual evidence in regulatory decision-making.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag296","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T11:40:57Z","timestamp":1784979657000},"source":"Crossref","is-referenced-by-count":0,"title":["Use of real-world evidence in the U.S. Food and Drug Administration and the European Medicines Agency approvals of oncology products supported by single-arm trials (2022-2025)"],"prefix":"10.1093","volume":"31","author":[{"given":"Le","family":"Su","sequence":"first","affiliation":[{"name":"Merck & Co., Inc. , Rahway, NJ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Chen","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc. , Rahway, NJ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8267-5356","authenticated-orcid":false,"given":"Ronac","family":"Mamtani","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Betigeri","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc. , Rahway, NJ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Hubbard","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Brown University School of Public Health , Providence, RI,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4572-0987","authenticated-orcid":false,"given":"Mehmet","family":"Burcu","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc. , Rahway, NJ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"key":"2026082812192627200_oyag296-B1","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1001\/jamaoncol.2022.5985","article-title":"Use of single-arm trials for US Food and Drug Administration drug approval in oncology, 2002-2021","volume":"9","author":"Agrawal","year":"2023","journal-title":"JAMA Oncol"},{"key":"2026082812192627200_oyag296-B2","doi-asserted-by":"crossref","first-page":"101209","DOI":"10.1016\/j.esmoop.2023.101209","article-title":"Single-arm trials supporting the approval of anticancer medicinal products in the European Union: contextualization of trial results and observed clinical benefit","volume":"8","author":"Mulder","year":"2023","journal-title":"ESMO Open"},{"key":"2026082812192627200_oyag296-B3","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1056\/NEJMp2200089","article-title":"Real-world evidence\u2013where are we now?","volume":"386","year":"2022","journal-title":"N Engl J Med"},{"key":"2026082812192627200_oyag296-B4","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1002\/cpt.70033","article-title":"Clinical trials with pragmatic elements: a review of use cases and real-world data utilization","volume":"118","author":"Su","year":"2025","journal-title":"Clin Pharmacol Ther"},{"key":"2026082812192627200_oyag296-B5","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/oncolo\/oyab071","article-title":"Blurring the lines of design: prospective observational cohorts and pragmatic clinical trials characterizing treatment effects in routine cancer care","volume":"27","author":"Rivera","year":"2022","journal-title":"Oncologist"},{"key":"2026082812192627200_oyag296-B6","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1002\/pds.4975","article-title":"Real-world evidence to support regulatory decision-making for medicines: considerations for external control arms","volume":"29","author":"Burcu","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2026082812192627200_oyag296-B7","doi-asserted-by":"crossref","first-page":"e746","DOI":"10.1634\/theoncologist.2019-0647","article-title":"Real-world evidence in oncology: opportunities and limitations","volume":"25","author":"Di Maio","year":"2020","journal-title":"Oncologist"},{"key":"2026082812192627200_oyag296-B8","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.jval.2020.06.006","article-title":"Use of real-world evidence to support FDA approval of oncology drugs","volume":"23","author":"Feinberg","year":"2020","journal-title":"Value Health"},{"key":"2026082812192627200_oyag296-B9","doi-asserted-by":"crossref","first-page":"e13903","DOI":"10.1111\/cts.13903","article-title":"Real-world evidence to support regulatory submissions: a landscape review and assessment of use cases","volume":"17","author":"Alipour-Haris","year":"2024","journal-title":"Clinical Translational Sci"},{"key":"2026082812192627200_oyag296-B10","author":"Medicines and Healthcare Products Regulatory Agency (MHRA)","year":"2025"},{"key":"2026082812192627200_oyag296-B11","author":"Canadian Agency for Drugs and Technologies in Health (CADTH), Health Canada, and Institut National D\u2019excellence en Sant\u00e9 et en Services Sociaux (INESSS)","year":"2023"},{"key":"2026082812192627200_oyag296-B12","volume-title":"Considerations for the Design and Conduct of Externally Controlled Trials for Drug and Biological Products (Draft Guidance)","author":"U.S. Food and Drug Administration","year":"2023"},{"key":"2026082812192627200_oyag296-B13","author":"European Medicines Agency","year":"2023"},{"key":"2026082812192627200_oyag296-B14","author":"European Medicines Agency","year":"2025"},{"key":"2026082812192627200_oyag296-B15","author":"U.S. Food and Drug Administration","year":"2024"},{"key":"2026082812192627200_oyag296-B16","author":"U.S. Food and Drug Administration","year":"2022"},{"key":"2026082812192627200_oyag296-B17","volume-title":"Considerations for the Use of Real-World Data and Real-World Evidence to Support Regulatory Decision-Making for Drug and Biological Products","author":"U.S. Food and Drug Administration","year":"2023"},{"key":"2026082812192627200_oyag296-B18","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1158\/1078-0432.CCR-25-1255","article-title":"Diversity by design: real-world data to enhance representation in clinical cancer research","volume":"31","author":"Vo","year":"2025","journal-title":"Clin Cancer Res"},{"key":"2026082812192627200_oyag296-B19","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s43441-021-00322-8","article-title":"A framework for extension studies using real-world data to examine long-term safety and effectiveness","volume":"56","author":"Burcu","year":"2022","journal-title":"Ther Innov Regul Sci"},{"key":"2026082812192627200_oyag296-B20","doi-asserted-by":"crossref","first-page":"e731","DOI":"10.1093\/oncolo\/oyac114","article-title":"Rationale, strengths, and limitations of real-world evidence in oncology: a Canadian review and perspective","volume":"27","author":"Azoulay","year":"2022","journal-title":"Oncologist"},{"key":"2026082812192627200_oyag296-B21","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.annonc.2023.10.001","article-title":"ESMO guidance for reporting oncology real-world evidence (GROW)","volume":"34","author":"Castelo-Branco","year":"2023","journal-title":"Ann Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/9\/oyag296\/70828610\/oyag296.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/9\/oyag296\/70828610\/oyag296.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T16:19:34Z","timestamp":1787933974000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag296\/8772387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,8,6]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag296","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,8,6]]},"article-number":"oyag296"}}